 |
PDBsum entry 2i9a
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.73
- u-plasminogen activator.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
363:482-495
(2006)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
|
|
C.Barinka,
G.Parry,
J.Callahan,
D.E.Shaw,
A.Kuo,
K.Bdeir,
D.B.Cines,
A.Mazar,
J.Lubkowski.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Recent studies indicate that binding of the urokinase-type plasminogen activator
(uPA) to its high-affinity receptor (uPAR) orchestrates uPAR interactions with
other cellular components that play a pivotal role in diverse
(patho-)physiological processes, including wound healing, angiogenesis,
inflammation, and cancer metastasis. However, notwithstanding the wealth of
biochemical data available describing the activities of uPAR, little is known
about the exact mode of uPAR/uPA interactions or the presumed conformational
changes that accompany uPA/uPAR engagement. Here, we report the crystal
structure of soluble urokinase plasminogen activator receptor (suPAR), which
contains the three domains of the wild-type receptor but lacks the cell-surface
anchoring sequence, in complex with the amino-terminal fragment of
urokinase-type plasminogen activator (ATF), at the resolution of 2.8 A. We
report the 1.9 A crystal structure of free ATF. Our results provide a structural
basis, represented by conformational changes induced in uPAR, for several
published biochemical observations describing the nature of uPAR/uPA
interactions and provide insight into mechanisms that may be responsible for the
cellular responses induced by uPA binding.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. A representation of ATF binding to uPAR. Domains
D^I (amino acid residues 1–93), D^II (residues 94–191) and
D^III (residues 192–277) of suPAR are shown in yellow, blue,
and red, respectively; KD (residues 47–132) is in green, GFD
(residues 10–46) in magenta. (a) A cartoon representation of
the suPAR[2345]/ATF complex. The individual β-strands of
suPAR[2345] are labeled according to Llinas et al.^30 and Low et
al.^31 Domain D^I: βIA (residues 2–8), βIB (13–17), βIC
(24–33), βID (38–45), βIE (53–59), and βIF (63–70);
domain D^II: βIIA (94–100), βIIB (112–115), βIIC
(122–129), βIID (143–149), βIIE (156–161), and βIIF
(163–171); domain D^III: βIIIA (195–199), βIIIB
(211–214), βIIIC (222–229), βIIID (236–243), and βIIIE
(259–267). Contacts between the domains are mediated
via interactions βIE and βIID (domains D^I and D^II), βIIE
and βIIID (domains D^II and D^III). (b) The ATF (cartoon
representation) binds to the central cavity of suPAR[2345]
(surface representation) and the Ω-loop (Cys19–Cys31,
ball-and-sticks) is primarily responsible for the high-affinity
binding. Residues of suPAR[2345] interacting with ATF are in
cyan.
|
 |
Figure 5.
Figure 5. Repositioning of the “integrin-interacting”
loop (Trp129–Arg142) in suPAR[2345] upon ATF binding.
Interactions between amino acid residues Cys19–Lys23 of the
ATF and Pro138–Asp140 of suPAR[2345] leads to bending of the
loop towards the central cavity of the receptor. (a) The
complexes, suPAR[2345]/ATF (domains D^I, D^II and D^III colored
yellow, blue and red, respectively) and suPAR/AE147 (shown in
gray), were aligned on the basis of the corresponding C^α atoms
of domain D^I only. GFD is shown as a combination of
ball-and-sticks and semi-transparent surface. The βIIC-βIID
hairpin is in cartoon representation and its residues
interacting with GFD as ball-and-sticks. (b) A detailed view of
residues engaged in the interactions between strands βIIC and
βIID of suPAR[2345] and the Ω-loop of ATF. The Ω-loop is
shown in surface representation and the interacting residues
contributed by domain D^II are shown as balls-and-sticks. Note
the major movement of the βIIC-βIID hairpin caused by
interactions with the Ω-loop. In both structures, amino acid
residues 132 through 136 of suPAR are missing.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2006,
363,
482-495)
copyright 2006.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
K.Bifulco,
I.Longanesi-Cattani,
M.T.Masucci,
A.De Chiara,
F.Fazioli,
G.Di Carluccio,
G.Pirozzi,
M.Gallo,
A.La Rocca,
G.Apice,
G.Rocco,
and
M.V.Carriero
(2011).
Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.
|
| |
Sarcoma,
2011,
842842.
|
 |
|
|
|
|
 |
K.Bifulco,
I.Longanesi-Cattani,
M.Gala,
G.DI Carluccio,
M.T.Masucci,
V.Pavone,
L.Lista,
C.Arra,
M.P.Stoppelli,
and
M.V.Carriero
(2010).
The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.
|
| |
J Thromb Haemost,
8,
2789-2799.
|
 |
|
|
|
|
 |
L.Teimoori-Toolabi,
K.Azadmanesh,
A.Amanzadeh,
and
S.Zeinali
(2010).
Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter.
|
| |
BioDrugs,
24,
131-146.
|
 |
|
|
|
|
 |
D.C.Rijken,
and
H.R.Lijnen
(2009).
New insights into the molecular mechanisms of the fibrinolytic system.
|
| |
J Thromb Haemost,
7,
4.
|
 |
|
|
|
|
 |
A.Galat,
G.Gross,
P.Drevet,
A.Sato,
and
A.Ménez
(2008).
Conserved structural determinants in three-fingered protein domains.
|
| |
FEBS J,
275,
3207-3225.
|
 |
|
|
|
|
 |
B.Degryse,
J.Fernandez-Recio,
V.Citro,
F.Blasi,
and
M.V.Cubellis
(2008).
In silico docking of urokinase plasminogen activator and integrins.
|
| |
BMC Bioinformatics,
9,
S8.
|
 |
|
|
|
|
 |
D.E.Klein,
S.E.Stayrook,
F.Shi,
K.Narayan,
and
M.A.Lemmon
(2008).
Structural basis for EGFR ligand sequestration by Argos.
|
| |
Nature,
453,
1271-1275.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
V.V.Stepanova,
I.B.Beloglazova,
Y.G.Gursky,
R.S.Bibilashvily,
Y.V.Parfyonova,
and
V.A.Tkachuk
(2008).
Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis.
|
| |
Biochemistry (Mosc),
73,
252-260.
|
 |
|
|
|
|
 |
Y.Liu,
D.J.Cao,
I.M.Sainz,
Y.L.Guo,
and
R.W.Colman
(2008).
The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization.
|
| |
Am J Physiol Cell Physiol,
295,
C257-C267.
|
 |
|
|
|
|
 |
C.D.Madsen,
G.M.Ferraris,
A.Andolfo,
O.Cunningham,
and
N.Sidenius
(2007).
uPAR-induced cell adhesion and migration: vitronectin provides the key.
|
| |
J Cell Biol,
177,
927-939.
|
 |
|
|
|
|
 |
H.Gårdsvoll,
and
M.Ploug
(2007).
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
|
| |
J Biol Chem,
282,
13561-13572.
|
 |
|
|
|
|
 |
M.Hasanuzzaman,
R.Kutner,
S.Agha-Mohammadi,
J.Reiser,
and
I.Sehgal
(2007).
A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines.
|
| |
Mol Cancer,
6,
34.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |